International Observation of Antiphospholipid Patients Treated with DOACs
Part of Immune system & allergy clinical trials.
This research study looks at people with antiphospholipid syndrome (APS) who have taken or are taking direct oral anticoagulants (DOACs), which are blood thinners. The goal is to collect information about their treatment and health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have antiphospholipid syndrome (APS) with a blood clot (thrombosis) diagnosed using Sydney criteria.
- You are currently taking or have taken a direct oral anticoagulant (DOAC) blood thinner.
- You have been informed about the study and do not object to your data being used.
- You do not have triple antiphospholipid antibody positivity (a specific lab result).
- You have never had an arterial (artery) blood clot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (DOACs like rivaroxaban/apixaban vs. warfarin) in people with antiphospholipid syndrome who have had a vein clot. The goal is to see which works better to prevent future clots.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.